Genome-wide association studies suggest that Myo19 may involve in ovarian cancer, pancreatic ductal adenocarcinoma and breast cancer but whether it may play a tumor suppressive role is unclear62–67. This evidence concerns the gene MYO19 and ovarian carcinoma.